Astec LifeSciences Limited (ASTEC) - Total Liabilities
Based on the latest financial reports, Astec LifeSciences Limited (ASTEC) has total liabilities worth Rs4.69 Billion INR (≈ $50.73 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Astec LifeSciences Limited (ASTEC) investment intensity to see how much of total assets are deployed in long-term investments.
Astec LifeSciences Limited - Total Liabilities Trend (2008–2025)
This chart illustrates how Astec LifeSciences Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Astec LifeSciences Limited total assets.
Astec LifeSciences Limited Competitors by Total Liabilities
The table below lists competitors of Astec LifeSciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Laguna Resorts & Hotels Public Company Limited
BK:LRH
|
Thailand | ฿16.92 Billion |
|
Shangri-La Hotel Public Company Limited
BK:SHANG
|
Thailand | ฿528.09 Million |
|
Amaero Ltd
AU:3DA
|
Australia | AU$36.85 Million |
|
Vestel Elektronik Sanayi ve Ticaret AS
IS:VESTL
|
Turkey | TL155.67 Billion |
|
Kolibri Global Energy Inc
TO:KEI
|
Canada | CA$80.89 Million |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
USA | $727.22 Million |
|
Aplicaciones y Tratamiento de Sistemas S.A.
MC:ATSI
|
Spain | €78.36 Million |
|
Sparebank 1 Nordvest
OL:SNOR
|
Norway | Nkr25.68 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Astec LifeSciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ASTEC net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Astec LifeSciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Astec LifeSciences Limited (2008–2025)
The table below shows the annual total liabilities of Astec LifeSciences Limited from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs6.46 Billion ≈ $69.91 Million |
+6.77% |
| 2024-03-31 | Rs6.05 Billion ≈ $65.47 Million |
+8.14% |
| 2023-03-31 | Rs5.60 Billion ≈ $60.55 Million |
+11.95% |
| 2022-03-31 | Rs5.00 Billion ≈ $54.08 Million |
+35.80% |
| 2021-03-31 | Rs3.68 Billion ≈ $39.83 Million |
+13.37% |
| 2020-03-31 | Rs3.25 Billion ≈ $35.13 Million |
+25.76% |
| 2019-03-31 | Rs2.58 Billion ≈ $27.93 Million |
+6.18% |
| 2018-03-31 | Rs2.43 Billion ≈ $26.31 Million |
+24.48% |
| 2017-03-31 | Rs1.95 Billion ≈ $21.13 Million |
-23.21% |
| 2016-03-31 | Rs2.54 Billion ≈ $27.52 Million |
+11.75% |
| 2015-03-31 | Rs2.28 Billion ≈ $24.63 Million |
+32.85% |
| 2014-03-31 | Rs1.71 Billion ≈ $18.54 Million |
+10.44% |
| 2013-03-31 | Rs1.55 Billion ≈ $16.79 Million |
+16.94% |
| 2012-03-31 | Rs1.33 Billion ≈ $14.35 Million |
+61.59% |
| 2011-03-31 | Rs821.40 Million ≈ $8.88 Million |
+35.52% |
| 2010-03-31 | Rs606.13 Million ≈ $6.56 Million |
-6.89% |
| 2009-03-31 | Rs650.98 Million ≈ $7.04 Million |
+17.16% |
| 2008-03-31 | Rs555.62 Million ≈ $6.01 Million |
-- |
About Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maiz… Read more